PIONEER big data platform for prostate cancer: lessons for advancing future real-world evidence research
- PMID: 39251785
- DOI: 10.1038/s41585-024-00925-4
PIONEER big data platform for prostate cancer: lessons for advancing future real-world evidence research
Abstract
Prostate Cancer Diagnosis and Treatment Enhancement through the Power of Big Data in Europe (PIONEER) is a European network of excellence for big data in prostate cancer. PIONEER brings together 34 private and public stakeholders from 9 countries in one multidisciplinary research consortium with the aim of positively transforming the field of prostate cancer clinical care by answering pressing questions related to prostate cancer screening, diagnosis and treatment. PIONEER has developed a unique state-of-the-art big data analytic platform by integrating existing data sources from patients with prostate cancer. PIONEER leveraged this platform to address prioritized research questions, filling knowledge gaps in the characterization, management and core outcomes of prostate cancer across the different disease stages. The network has benefited from sustained patient and stakeholder involvement and engagement, but many challenges remain when using real-world data for big data projects. To continue to advance prostate cancer care, data need to be available, suitable methodologies should be selected and mechanisms for knowledge sharing must be in place. Now acting as the prostate cancer arm of the European Association of Urology's new endeavour, UroEvidenceHub, PIONEER maintains its goal of maximizing the potential of big data to improve prostate cancer care.
© 2024. Springer Nature Limited.
Conflict of interest statement
Competing interests: S.E.-A., J.B. and J.Z. are employees of Bayer; T.H. is an employee of Philips; R.S. and K.P. are employees of Astellas Pharma; T.A. was an employee of Astellas Pharma during the PIONEER project prior to retirement; A.B. has been a consultant and adviser for Accord, Astellas Pharma, AstraZeneca, Bayer, J&J and Pfizer and a board member, officer and trustee for Glactone Pharma, has received lecture honoraria for Accord, Astellas, AstraZeneca, Bayer, Ipsen, J&J and Merck, has participated in trials run by Astellas, Bayer, Ferring, Janssen and Pfizer, and holds stock in Glactone Pharma, LIDDS Pharma and WntResearch. All companies make products used to treat prostate cancer. The other authors declare no competing interests.
References
-
- Global Cancer Observatory. Cancer Today. International Agency for Research on Cancer https://gco.iarc.fr/today/en (2023).
-
- Kalkman, S., Mostert, M., Udo-Beauvisage, N., van Delden, J. J. & van Thiel, G. J. Responsible data sharing a big data-driven translational research platform: lessons learned. BMC Med. Inf. Decis. Mak. 19, 283 (2019). - DOI
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
